Instrument Inactif

Communiqués Nanosphere, Inc. Nasdaq

Actions

US63009F1057

Equipement et technologie médicale avancés

Communiqués

20/06/16	Nanosphere Announces Intent to Voluntarily Delist From NASDAQ Capital Market	GL
16/05/16	Nanosphere Announces First Quarter Results	GL
03/03/16	Nanosphere’s Verigene BC-GP Decreases Patient Length of Stay	GL
24/02/16	Nanosphere Announces Fourth Quarter and Full Year 2015 Results, 2016 Guidance and Next Generation Verigene Progress	GL
11/02/16	Nanosphere to Announce Fourth Quarter Financial Results and Host Investor Call on Wednesday, February 24	GL
06/01/16	Nanosphere Announces Record Preliminary Q4 and Full Year 2015 Results	GL
23/12/15	Verigene® BC-GN Positioned to Provide Rapid Diagnosis of “Phantom Menace” Superbug	GL
22/12/15	Nanosphere, Inc. Announces Completion of $10 Million Registered Public Offering	GL
18/12/15	Nanosphere : Announces $10 Million Registered Public Offering	PU
09/11/15	Nanosphere Announces Record Q3 2015 Results	GL
02/11/15	Nanosphere to Announce Third Quarter Financial Results & Host Investor Call on Monday, November 9	GL
22/09/15	Impact of Verigene Blood Culture Tests Highlighted by Five Studies Presented at ICAAC 2015	GL
08/09/15	Nanosphere Receives FDA Clearance for First-of-Its-Kind Flexible Respiratory Pathogens Test	GL
10/08/15	Nanosphere Announces Record Q2 2015 Results	GL
31/07/15	Nanosphere Announces Amendment to $30 Million Term Loan Facility, Release of Q2 2015 Results and Conference Call and Schedules 2015 Annual Meeting of Stockholders	GL
22/06/15	New Studies Highlight Antibiotic Resistance Detection With Nanosphere's Verigene Blood Culture Tests	GL
08/06/15	Nanosphere Announces $4.4 Million at the Market Registered Direct Offering	GL
27/05/15	Eighteen New Verigene Clinical and Economic Studies Presented at CVS, ECCMID and MAD-ID 2015	GL
15/05/15	Nanosphere Announces Closing of New and Expanded Debt Facility and $4.4 Million at the Market Registered Direct Offering	GL
11/05/15	Nanosphere Announces Record Q1 2015 Results, New and Expanded Debt Facility, $4.4 Million at the Market Registered Direct Offering and Next Generation Verigene System Progress	GL